Latest Headlines

  1. GE Healthcare Life Sciences Plans New Manufacturing Facility In Switzerland 1/22/2020

    GE Healthcare Life Sciences is building a new 7,360 square meter facility in Grens, Switzerland, in the new Signy Park, for the manufacture of single use kits for the Sepax and Sefia cell processing systems. The facility will meet global regulatory requirements and is expected to be fully operational in 2022.

  2. The Center For Breakthrough Medicines And Discovery Labs To Build World's Largest Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) 1/22/2020

    The Discovery Labs and Deerfield Management Company have formed The Center for Breakthrough Medicines, a Contract Development and Manufacturing Organization (CDMO) and specialty investment company, to alleviate the critical lack of capacity that is preventing patients from accessing critically needed cell and gene therapies.

  3. Werum IT Solutions Launches New Smart Biometric Authentication Solution K.ME-IN For Pharma And Biotech In Cooperation With Nymi 1/9/2020

    Werum IT Solutions is excited to announce the launch of K.ME-IN, a biometric authentication solution with Nymi for Werum’s PAS-X Manufacturing Execution System (MES). The new solution will allow users on the pharmaceutical or biopharmaceutical shop floor to securely and seamlessly authenticate to systems, devices and machines via a smart wristband. In the future, K.ME-IN will be extended to allow user authentication via further biometric means such as iris scan, face recognition, fingerprint or a combination of those.

  4. Tessa Therapeutics Announces Plans To Open New Cell Therapy Manufacturing Facility In Singapore In Late 2020 12/19/2019

    Tessa Therapeutics (Tessa), a clinical-stage cell therapy company focused on the development of innovative cell therapies to treat cancer, today announced plans to open a 90,000 square foot commercial-scale cell therapy manufacturing facility in Singapore by end-2020, which will be one of the leading commercial-scale cell therapy manufacturing facilities in Asia.

  5. RoosterBio Expands Maryland Facility For Regenerative Medicine Needs 12/19/2019

    RoosterBio Inc., a cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry, expanded its facility in Frederick, Maryland.

  6. GE Healthcare Life Sciences Allies With Pharmadule Morimatsu To Expand KUBio 12/5/2019

    The KUBio “factory in a box” is expanding to accelerate the accessibility of biotherapeutics on a global scale. Additional modular platforms will be introduced in 2020 allowing biopharma manufacturers to quickly scale up vaccines, viral vector-based therapies, and other novel modalities.

  7. Thermo Fisher Scientific Opens $90 Million Viral Vector Manufacturing Site in Massachusetts 12/5/2019

    New facility will create 200 new jobs and accelerate commercialization of gene and cell therapies.

  8. VGXI Selects BE&K As Design Firm For New 240,000 Square Foot Manufacturing Facility 12/3/2019

    VGXI, a highly regarded CDMO supporting the gene therapy and DNA vaccine industries, announces it has chosen the integrated construction services company BE&K Building Group as Design-Build Partner for the initial phase of its new manufacturing site.

  9. Astellas Buys Audentes Therapeutics For $3B For Gene Therapy Drug Manufacturing Expansion 12/2/2019

    Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Audentes Therapeutics, Inc. (Chairman and CEO: Matthew R. Patterson, “Audentes”), today announced that they have entered into a definitive agreement for Astellas to acquire Audentes at a price of US$60.00 per share in cash, representing a total equity value of approximately US$3B.

  10. Speeding Cell, Gene Therapy Development 11/25/2019

    An innovative new major private-public partnership led by Harvard and MIT aims to accelerate one of the hottest and most promising areas of medical research: cell and gene therapy